Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for MNKD.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2002. Start Trial.
Date Value
June 30, 2026 111.13M
March 31, 2026 133.86M
December 31, 2025 171.35M
September 30, 2025 260.04M
June 30, 2025 178.98M
March 31, 2025 181.54M
December 31, 2024 197.26M
September 30, 2024 251.59M
June 30, 2024 247.76M
March 31, 2024 300.73M
December 31, 2023 295.10M
September 30, 2023 141.02M
June 30, 2023 144.35M
March 31, 2023 166.14M
December 31, 2022 170.85M
September 30, 2022 165.05M
June 30, 2022 154.16M
March 31, 2022 162.45M
December 31, 2021 204.12M
September 30, 2021 139.05M
June 30, 2021 162.49M
March 31, 2021 276.95M
December 31, 2020 67.16M
September 30, 2020 52.71M
June 30, 2020 63.54M
Date Value
March 31, 2020 39.18M
December 31, 2019 50.20M
September 30, 2019 50.37M
June 30, 2019 38.19M
March 31, 2019 59.82M
December 31, 2018 71.68M
September 30, 2018 10.97M
June 30, 2018 26.70M
March 31, 2018 27.23M
December 31, 2017 48.36M
September 30, 2017 20.09M
June 30, 2017 43.38M
March 31, 2017 47.98M
December 31, 2016 23.24M
September 30, 2016 35.53M
June 30, 2016 63.73M
March 31, 2016 27.65M
December 31, 2015 59.07M
September 30, 2015 32.93M
June 30, 2015 107.19M
March 31, 2015 120.84M
December 31, 2014 120.84M
September 30, 2014 172.46M
June 30, 2014 41.21M
March 31, 2014 35.76M

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
United Therapeutics Corp. 2.662B
ACADIA Pharmaceuticals, Inc. 956.47M
Gilead Sciences, Inc. 4.882B
Vertex Pharmaceuticals, Inc. 7.863B
Ocugen, Inc. 100.05M